



# Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid

Augustus Hough<sup>1</sup> · Jessica Wearden<sup>2</sup> · Kristen de Almeida<sup>3</sup> · Stephanie Kaiser<sup>1</sup>

Published online: 28 September 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

**Correction to: Current Cardiology Reports (2020) 22:106**  
<https://doi.org/10.1007/s11886-020-01374-2>

On page 2 of the original publication, in the section on **TTR Silencers**, dosing of patisiran in the APOLLO study was stated as being given every 3 months; this is inaccurate as patisiran was dosed every 3 weeks in the APOLLO study. The corrected sentence is presented below:

“Patisiran, as an intravenous infusion every 3 weeks, also slowed functional decline versus placebo in the APOLLO study; however, in contrast to inotersen, 56% of patients had an improvement in functional outcomes from baseline [14].”

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s11886-020-01374-2>

---

✉ Augustus Hough  
Augustus.hough@va.gov

Jessica Wearden  
Jessica.wearden@va.gov

Kristen de Almeida  
KristenDe@baptisthealth.net

Stephanie Kaiser  
Stephanie.Kaiser@va.gov

<sup>1</sup> Clinical Pharmacy Specialist – Cardiology, West Palm Beach Veterans Affairs Medical Center, 7305 N. Military Trail, West Palm Beach, FL 33410, USA

<sup>2</sup> PGY2 Cardiology Pharmacy Practice Resident, West Palm Beach Veterans Affairs Medical Center, West Palm Beach, FL, USA

<sup>3</sup> Clinical Pharmacy Specialist – Cardiology, Baptist Hospital of Miami, 8900 N. Kendall Dr, Miami, FL 333176, USA